Understanding and combating complex diseases and the introduction of precision medicine is a difficult task that requires an integrated approach involving the use of well-defined study cohorts, use of proper clinical information and variable research methods, as well as proper action to translate the obtained knowledge for clinical use. Complex approaches involving omics-based (e.g. genomics, epigenomics, microbiome-based metagenomics, and metabolomics) are needed, complemented by a systematic use of good quality biological material and phenotypic data.
INTEGROMED project aims to increase the excellence of LBMC in research and innovation in the field of translational medicine using omics-based approaches targeted at metabolic disorders by capitalizing on knowledge transfer from three internationally renowned partners in the field of medical research - University of Dundee, Lund University, and Weizmann Institute of Science. INTEGROMED will develop a sustainable approach targeting virtually all aspects of translational medicine including the optimal use of clinical and biobank resources, integration of different omics in systemic workflow, reaching development of bedside applications, and fostering entrepreneurial.
INTEGROMED objectives are:
1) Improve and optimize the use of resources provided by large biobanks and prospective cohorts in combination with the national health care system, improve knowledge in the establishment of clinical studies for the development of precision medicine approaches.
2) Strengthen collaboration-based training of specialists in areas of multi-omics approaches, bioinformatics, and modeling to increase excellence in implementing cutting edge
multi-omics technologies in such areas as genomics, methylation, and expression profile, microbiome, and metabolome analysis.
3) Elaborate a long-term strategy and sustainability plan involving all relevant stakeholders, ensure development and training in clinical applications, and entrepreneurial skills to build an innovation ecosystem around LBMC.